The complexity of managing a patient with CTD-PAH can be dizzying. 😵‍💫 Our latest paper breaks down the management of these patients into practical pieces. journals.sagepub.com/doi/10.1177/...

Next-generation radiomic sequencing in non-small cell lung cancer: an alternative model to predict mutations from [18F]FDG PET/CT @tarespirdis.bsky.social @journals.sagepub.com journals.sagepub.com/doi/10.1177/... #NSCLC #radiomics #medicalimaging #precisiononcology #openaccess

Lungs on fire 🔥 - the ERS session on respiratory infections is about to kick off. Looking forward to insights from Associate Editor Tom Wilkinson, who's joining as a discussant. #ERSCongress2025 #ERS2025 #RespiratoryHealth

Later today Associate Editor Corrado Pelaia is chairing a session at #ERS2025: Remission/stability in airway diseases – how to achieve it and what’s next? Exploring strategies for long-term disease control and emerging research. #ERSCongress2025 #AirwayDiseases

At #ERS2025, Associate Editor Dr Shaney Barratt chaired a poster session on Clinical prognostication in pulmonary fibrosis. The session highlighted current approaches and future directions in predicting disease progression. #ERSCongress2025 #PulmonaryFibrosis

Great to connect with Editor-in-Chief Dr. Nazia Chaudhuri and several Associate Editors of Therapeutic Advances in Respiratory Disease at #ERSCongress2025 yesterday. Valuable discussions around editorial priorities and future plans! #ERS2025 #RespiratoryDisease @ild-ipfdoc.bsky.social

🔥 Lungs on Fire: Interstitial Lung Diseases is now live at #ERS2025 - a packed session co-chaired by our Editor-in-Chief, Dr Nazia Chaudhuri. #ERSCongress

📣Just published: a plain language summary of publication exploring how doctors and patients communicate about treatment for systemic sclerosis-associated interstitial lung disease. 👉Read it here: journals.sagepub.com/doi/full/10.... #SSc #ILD

It's our second day at #ERS2025! Today’s programme includes sessions chaired by our Associate Editors and Editor-in-Chief. Looking forward to the discussions ahead. #ERSCongress

📢About to begin: ALERT 2 – Infections, Lung Cancer and Respiratory Symptoms Management Chaired by our Associate Editor Tom Wilkinson, with editorial board member Francesco Blasi joining as a discussant. Looking forward to catching some of the insights!🫁 #ERSCongress2025

Enjoyed the session on Emerging Clinical Trials in Pulmonary Fibrosis, co-chaired by our Editor-in-Chief Dr. Nazia Chaudhuri. A popular and timely discussion with lots of interest from attendees. #ERS2025 #ERSCongress2025 #ClinicalTrials

Great turnout at ALERT 1: Obstructive Airway Diseases in Children and Adults, with our Associate Editor Prof Antonio Spanevello contributing as a discussant. Engaging presentations and valuable discussion made this a great session🫁 #ERS2025 #RespiratoryMedicine #ERSCongress

📍#ERSCongress Check out this fascinating abstract: “Mepolizumab induces proteome changes in eosinophils from severe eosinophilic asthma” - coauthored by our editorial board member Francisco-Javier Gonzalez-Barcala. #ERS2025 #Asthma

Excited to be at #ERSCongress today! Looking forward to sharing highlights from sessions and posters - including some fantastic contributions from our board. Stay tuned for updates throughout the day 🫁✨ #ERS2025 #RespiratoryMedicine

📍 Heading to Amsterdam for #ERSCongress this week! Looking forward to connecting with our Editorial Board Members and engaging with the latest developments in respiratory research. If you're attending, feel free to get in touch! Follow along for updates from the congress! 🫁

The correlation between the level of therapy adherence and inhalation technique in children with uncontrolled asthma using a smart inhaler: the IMAGINE study @tarespirdis.bsky.social @journals.sagepub.com journals.sagepub.com/doi/10.1177/... #ehealth #pediatric #medicine #medsky #openaccess

Efficacy of respiratory muscle training in improving pulmonary function and survival in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis @tarespirdis.bsky.social @journals.sagepub.com journals.sagepub.com/doi/10.1177/... #ALS #neuromuscular #healthcare #openaccess

Therapeutic options for patients with pulmonary hypertension and interstitial lung disease @tarespirdis.bsky.social @journals.sagepub.com journals.sagepub.com/doi/10.1177/... #respiratorydisease #treatment #medicine #medsky #openaccess

Advances in diagnosis and patient profiling in pulmonary arterial hypertension for precision medicine @tarespirdis.bsky.social @journals.sagepub.com journals.sagepub.com/doi/10.1177/... #artificialintelligence #genetictesting #medsky #lungdisease #openaccess

Immunosuppression is a core part of managing interstitial lung diseases. Learn how outcomes differ between antisynthetase syndrome and systemic sclerosis in response to treatment! journals.sagepub.com/doi/full/10....

Don't lose the forest for the trees! Check out this forest plot in our latest meta-analysis on cardiovascular risk in patients with asthma! journals.sagepub.com/doi/10.1177/...

🔥Hot off the press! Glucocorticoids are a cornerstone of therapy for many respiratory conditions. However, there are unintended effects. Here's a comprehensive review of the impact of cumulative glucocorticoid dosage in immunocompromised patients. journals.sagepub.com/doi/10.1177/...

Severe asthma is a deadly disease ☠️ Read the latest review on inhaled triple therapy in patients with severe asthma! journals.sagepub.com/doi/10.1177/...

April is Sarcoidosis Awareness Month. Throwback to our paper on the management of sarcoidosis. journals.sagepub.com/doi/full/10....

From targeted therapy to multidisciplinary management, Cystic Fibrosis has outlined a standard model for research and management of complex respiratory diseases. Please check out our latest review! journals.sagepub.com/doi/10.1177/...

COPD affects over 300 million individuals across the globe. Please read our latest review of the literature summarizing the mechanisms that lead to exacerbations of this deadly respiratory disease. #COPD journals.sagepub.com/doi/epdf/10....

📈 Trending this month: Symptom versus exacerbation control: an evolution in GINA guidelines? This review explores 25 years of shifting priorities in asthma management—from symptom relief to preventing exacerbations. 🔗 journals.sagepub.com/doi/epdf/10....

🫁 Patients with pulmonary fibrosis & pulmonary hypertension treated with both antifibrotics and pulmonary vasodilators had significantly better transplant-free survival vs antifibrotics alone (HR 0.24, p=0.04), despite worse baseline hemodynamics. 🔗 journals.sagepub.com/doi/epdf/10....

🏃 HIIT and MICT were the most effective lower limb aerobic training types for COPD, improving exercise capacity, lung function, breathlessness, and quality of life. HICT showed similar gains but caused more dyspnea. 🔗 journals.sagepub.com/doi/epdf/10....

🫁 Pulmonary rehab significantly improved physical capacity, lung function, QoL, fatigue, dyspnea, and anxiety in long COVID-19 patients across 37 RCTs (n=3,363). Best results with 4–8 week programs combining breathing and multicomponent exercises. 🔗 journals.sagepub.com/doi/epdf/10....

🫁 Multidisciplinary discussion (MDD) significantly altered the diagnosis in 61% of interstitial lung disease (ILD) patients, with notable shifts even in confirmed IPF cases. MDD also influenced prognosis, highlighting its vital role in ILD care. 🔗 journals.sagepub.com/doi/epdf/10....

A new CT-based decision tree algorithm predicts recurrence/metastasis risk in stage I SMPLC. Built on 5 key imaging parameters, the model showed AUC > 0.80 across cohorts and subgroups—supporting its role as a practical, noninvasive risk tool. 🔗 journals.sagepub.com/doi/epdf/10....

This plain language summary reviews key findings from the GALATHEA & TERRANOVA studies on benralizumab for COPD. Insights from two major trials help identify which patients may benefit most from treatment. 🔗 Read more: journals.sagepub.com/doi/pdf/10.1...

A mixed-methods pilot study assessed domiciliary nasal high-flow therapy for people with COPD and severe breathlessness who do not qualify for long-term oxygen therapy. The findings show feasibility, patient adherence, and concerns about long-term use 🔗 journals.sagepub.com/doi/epdf/10....

Pulmonary nontuberculous mycobacterial infections (NTM-PD) are rising among women with cystic fibrosis (CF) and non-CF bronchiectasis. This review examines the epidemiology, treatment considerations, and research gaps in NTM-PD among women. 🔗 Read more: journals.sagepub.com/doi/epdf/10....